Studying gut bacteria and metformin in young people with type 1 diabetes
Tests metformin in youth with type 1 diabetes who are overweight or have obesity.
Plain-language title generated from the registry record
Registry title: The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
Key facts
- Where
- Indianapolis, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 11 and 18 years old?
Source: NCT05414409, who can take part
Where in United States
- Indiana University School of MedicineIndianapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Heba M. Ismail
- Trial code
- NCT05414409
- Record updated
- 21 August 2026
- Original description
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.Read full original descriptionShow less
The Gut Microbiome in Lean and Overweight Youth With Type 1 Diabetes and Novel Mechanism of Action of Metformin
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Inclusion: Overweight/obese youth 11-18 years of age with T1D at time of enrollment; Lean youth 11-18 years of age with T1D at time of enrollment.
Exclusion: Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing); History of ongoing infection or antibiotic treatment within the past month; History of immune-compromise, recurrent infections, steroid intake (inhaled or oral forms) or other immunosuppressant use in the past 6 months; History of chronic gastrointestinal disease and active within the past 6 months, possible or confirmed celiac disease; History of treatment or use of metformin, a type 2 diabetes medication; Participation in any research intervention trials within the past 3 months.